This week we are talking to Gary Robinson, a partner at Baillie Gifford and the manager of the Baillie Gifford US Growth Trust, a FTSE 250 constituent. It seems like a timely discussion with so much focus on the US market at the moment. and with hedge fund Saba Capital seeking to take control of the trust’s board.
On the podcast we chat about the investment trust’s strategy and especially its exposure to unlisted companies. We look at how the trust optimises its exposure to the US tech sector and whether the Mag 7 stocks are distracting tech investors from other opportunities. Gary also gives us his views on how to spot the next big technology success story.
It’s not all tech though: we also had time to look at the US healthcare sector and of course the likely impact of Donald Trump on the US stock market.
Listeners should be aware that the podcast was recorded prior to Saba Capital’s announcement on 18 December in which it said it would seek governance changes at seven listed trusts.
Listen: Baillie Gifford’s Gary Robinson on US growth stocks
Podcast content
00:00 Intro to the Baillie Gifford US Growth Trust
03:18 Private companies in the portfolio
06:21 Why large tech companies decide not to IPO
08:12 The Mag7 stocks
10:40 Finding the next Amazon NASDAQ:AMZN or Nvidia NASDAQ:NVDA
14:14 Corporate culture and visionary management teams
16:33 Healthcare sector holdings
19:04 Will the new presidency be good for US growth stocks?
21:38 Gary’s two favourite stocks
